High-Throughput MicroRNA (miRNAs) Arrays Unravel the Prognostic Role of MiR-211 in Pancreatic Cancer

Background Only a subset of radically resected pancreatic ductal adenocarcinoma (PDAC) patients benefit from chemotherapy, and identification of prognostic factors is warranted. Recently miRNAs emerged as diagnostic biomarkers and innovative therapeutic targets, while high-throughput arrays are opening new opportunities to evaluate whether they can predict clinical outcome. The present study evaluated whether comprehensive miRNA expression profiling correlated with overall survival (OS) in resected PDAC patients. Methodology/Principal Findings High-resolution miRNA profiles were obtained with the Toray's 3D-Gene™-miRNA-chip, detecting more than 1200 human miRNAs. RNA was successfully isolated from paraffin-embedded primary tumors of 19 out of 26 stage-pT3N1 homogeneously treated patients (adjuvant gemcitabine 1000 mg/m2/day, days-1/8/15, every 28days), carefully selected according to their outcome (OS<12 (N = 13) vs. OS>30 months (N = 6), i.e. short/long-OS). Highly stringent statistics included t-test, distance matrix with Spearman-ranked correlation, and iterative approaches. Unsupervised hierarchical analysis revealed that PDACs clustered according to their short/long-OS classification, while the feature selection algorithm RELIEF identified the top 4 discriminating miRNAs between the two groups. These miRNAs target more than 1500 transcripts, including 169 targeted by two or more. MiR-211 emerged as the best discriminating miRNA, with significantly higher expression in long- vs. short-OS patients. The expression of this miRNA was subsequently assessed by quantitative-PCR in an independent cohort of laser-microdissected PDACs from 60 resected patients treated with the same gemcitabine regimen. Patients with low miR-211 expression according to median value had a significantly shorter median OS (14.8, 95%CI = 13.1–16.5, vs. 25.7 months, 95%CI = 16.2–35.1, log-rank-P = 0.004). Multivariate analysis demonstrated that low miR-211 expression was an independent factor of poor prognosis (hazard ratio 2.3, P = 0.03) after adjusting for all the factors influencing outcome. Conclusions/Significance Through comprehensive microarray analysis and PCR validation we identified miR-211 as a prognostic factor in resected PDAC. These results prompt further prospective studies and research on the biological role of miR-211 in PDAC.

[1]  E. Giovannetti,et al.  Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice. , 2012, Critical reviews in oncology/hematology.

[2]  Xian-gui Hu,et al.  MicroRNA 483‐3p suppresses the expression of DPC4/Smad4 in pancreatic cancer , 2011, FEBS letters.

[3]  T. Brenn,et al.  Differential expression of microRNAs during melanoma progression: miR-200c, miR-205 and miR-211 are downregulated in melanoma and act as tumour suppressors , 2012, British Journal of Cancer.

[4]  Thomas D. Schmittgen,et al.  Antisense Inhibition of microRNA-21 or -221 Arrests Cell Cycle, Induces Apoptosis, and Sensitizes the Effects of Gemcitabine in Pancreatic Adenocarcinoma , 2009, Pancreas.

[5]  K. Ohuchida,et al.  MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance , 2009, Molecular Cancer Therapeutics.

[6]  S. T. Mees,et al.  MicroRNAs: Novel Diagnostic and Therapeutic Tools for Pancreatic Ductal Adenocarcinoma? , 2009, Annals of Surgical Oncology.

[7]  Fionn Murtagh,et al.  Multidimensional clustering algorithms , 1985 .

[8]  M. Saif.  Controversies in the adjuvant treatment of pancreatic adenocarcinoma. , 2007, JOP : Journal of the pancreas.

[9]  C. Croce,et al.  MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. , 2007, JAMA.

[10]  U. Boggi,et al.  Prognostic implications of tumor invasion or adhesion to peripancreatic vessels in resected pancreatic cancer. , 2009, Surgery.

[11]  E. Giovannetti,et al.  Critical role of laser microdissection for genetic, epigenetic and proteomic analyses in pancreatic cancer , 2011, Expert review of molecular diagnostics.

[12]  Edgar Acuña,et al.  The Treatment of Missing Values and its Effect on Classifier Accuracy , 2004 .

[13]  M. Hashizume,et al.  MicroRNA Expression as a Predictive Marker for Gemcitabine Response after Surgical Resection of Pancreatic Cancer , 2011, Annals of Surgical Oncology.

[14]  H. Ashktorab,et al.  MicroRNA-211 Expression Promotes Colorectal Cancer Cell Growth In Vitro and In Vivo by Targeting Tumor Suppressor CHD5 , 2012, PloS one.

[15]  Weihua Hu,et al.  Association between High miR-211 microRNA Expression and the Poor Prognosis of Oral Carcinoma , 2008, Journal of dental research.

[16]  Yong-Tae Kim,et al.  Identification of MicroRNA-21 as a Biomarker for Chemoresistance and Clinical Outcome Following Adjuvant Therapy in Resectable Pancreatic Cancer , 2010, PloS one.

[17]  Franco Mosca,et al.  Laser microdissection and primary cell cultures improve pharmacogenetic analysis in pancreatic adenocarcinoma , 2008, Laboratory Investigation.

[18]  I. Bozzoni,et al.  Concerted microRNA control of Hedgehog signalling in cerebellar neuronal progenitor and tumour cells , 2008, The EMBO journal.

[19]  Andreas Keller,et al.  MicroRNAs Targeting Oncogenes Are Down-Regulated in Pancreatic Malignant Transformation from Benign Tumors , 2012, PloS one.

[20]  R. Stephens,et al.  The Identification of MicroRNAs in a Genomically Unstable Region of Human Chromosome 8q24 , 2008, Molecular Cancer Research.

[21]  H. Kocher,et al.  Pancreatic Cancer , 2019, Methods in Molecular Biology.

[22]  Malte Buchholz,et al.  Stromal biology and therapy in pancreatic cancer , 2010, Gut.

[23]  Tommaso Mazza,et al.  Mirna Expression Profiles Identify Drivers in Colorectal and Pancreatic Cancers , 2012, PloS one.

[24]  J. Donohue,et al.  Long-Term Survival After Pancreatoduodenectomy for Pancreatic Adenocarcinoma: Is Cure Possible? , 2008, Annals of surgery.

[25]  Franco Mosca,et al.  Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. , 2006, Cancer research.

[26]  Laura H. Tang,et al.  Pancreatic Adenocarcinoma: The Actual 5-Year Survivors , 2008, Journal of Gastrointestinal Surgery.

[27]  Lin He,et al.  MicroRNAs: small RNAs with a big role in gene regulation , 2004, Nature Reviews Genetics.

[28]  A. Adai,et al.  Global microRNA expression profiling of microdissected tissues identifies miR‐135b as a novel biomarker for pancreatic ductal adenocarcinoma , 2012, International journal of cancer.

[29]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[30]  Hong Wu,et al.  Integrative Survival-Based Molecular Profiling of Human Pancreatic Cancer , 2012, Clinical Cancer Research.

[31]  Hyunsuk Shim,et al.  Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. , 2010, Biochemical pharmacology.

[32]  Yunqing Li,et al.  The Neuronal MicroRNA miR-326 Acts in a Feedback Loop with Notch and Has Therapeutic Potential against Brain Tumors , 2009, The Journal of Neuroscience.

[33]  Jennifer P Morton,et al.  MicroRNA Molecular Profiles Associated with Diagnosis, Clinicopathologic Criteria, and Overall Survival in Patients with Resectable Pancreatic Ductal Adenocarcinoma , 2011, Clinical Cancer Research.

[34]  G. Tsujimoto,et al.  MicroRNA Profile Predicts Recurrence after Resection in Patients with Hepatocellular Carcinoma within the Milan Criteria , 2011, PloS one.

[35]  Qizhi Yao,et al.  Profiling of 95 MicroRNAs in Pancreatic Cancer Cell Lines and Surgical Specimens by Real-Time PCR Analysis , 2009, World Journal of Surgery.

[36]  J. Abbruzzese.  Adjuvant therapy for surgically resected pancreatic adenocarcinoma. , 2008, JAMA.

[37]  Ugo Boggi,et al.  MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. , 2010, Cancer research.

[38]  W. Fujibuchi,et al.  MiR-126 Acts as a Tumor Suppressor in Pancreatic Cancer Cells via the Regulation of ADAM9 , 2011, Molecular Cancer Research.

[39]  S. Sen,et al.  MicroRNA functional network in pancreatic cancer: From biology to biomarkers of disease , 2011, Journal of Biosciences.

[40]  C. Haglund,et al.  Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry , 2005, Gut.

[41]  T. Davison,et al.  MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma , 2007, Oncogene.

[42]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[43]  H. Horvitz,et al.  MicroRNA expression profiles classify human cancers , 2005, Nature.

[44]  Thomas D. Schmittgen,et al.  Expression profiling identifies microRNA signature in pancreatic cancer , 2006, International journal of cancer.

[45]  L. Mcquitty.  Similarity Analysis by Reciprocal Pairs for Discrete and Continuous Data , 1966 .

[46]  Wendy Frankel,et al.  MicroRNA-21 is Overexpressed in Pancreatic Cancer and a Potential Predictor of Survival , 2008, Journal of Gastrointestinal Surgery.

[47]  Ana Kozomara,et al.  miRBase: integrating microRNA annotation and deep-sequencing data , 2010, Nucleic Acids Res..

[48]  Dileep N. Lobo,et al.  Knockdown of microRNA-21 Inhibits Proliferation and Increases Cell Death by Targeting Programmed Cell Death 4 (PDCD4) in Pancreatic Ductal Adenocarcinoma , 2010, Journal of Gastrointestinal Surgery.

[49]  A. Jimeno,et al.  Molecular biomarkers: their increasing role in the diagnosis, characterization, and therapy guidance in pancreatic cancer , 2006, Molecular Cancer Therapeutics.

[50]  F. Slack,et al.  OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma , 2010, Nature.

[51]  D. Khaitan,et al.  The Regulation of miRNA-211 Expression and Its Role in Melanoma Cell Invasiveness , 2010, PloS one.

[52]  C. Croce,et al.  MicroRNA signatures in human cancers , 2006, Nature Reviews Cancer.

[53]  G. Parmigiani,et al.  Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.

[54]  Marko Robnik-Sikonja,et al.  Overcoming the Myopia of Inductive Learning Algorithms with RELIEFF , 2004, Applied Intelligence.

[55]  P. Meltzer,et al.  Loss of 18q22.3 Involving the Carboxypeptidase of Glutamate-like Gene Is Associated with Poor Prognosis in Resected Pancreatic Cancer , 2011, Clinical Cancer Research.

[56]  Larry A. Rendell,et al.  The Feature Selection Problem: Traditional Methods and a New Algorithm , 1992, AAAI.

[57]  Min Zhang,et al.  MicroRNA miR-34 Inhibits Human Pancreatic Cancer Tumor-Initiating Cells , 2009, PloS one.

[58]  Jun S. Song,et al.  Intronic miR-211 assumes the tumor suppressive function of its host gene in melanoma. , 2010, Molecular cell.

[59]  Dong Tang,et al.  Expression and promoter methylation analysis of ATP-binding cassette genes in pancreatic cancer. , 2011, Oncology reports.

[60]  Elke Hacker,et al.  Melanoma cell invasiveness is regulated by miR‐211 suppression of the BRN2 transcription factor , 2011, Pigment cell & melanoma research.

[61]  Gozoh Tsujimoto,et al.  Intra-Platform Repeatability and Inter-Platform Comparability of MicroRNA Microarray Technology , 2009, PloS one.

[62]  Judy M. Anderson,et al.  A Six-Gene Signature Predicts Survival of Patients with Localized Pancreatic Ductal Adenocarcinoma , 2010, PLoS medicine.

[63]  L. Goff,et al.  Ago2 Immunoprecipitation Identifies Predicted MicroRNAs in Human Embryonic Stem Cells and Neural Precursors , 2009, PloS one.

[64]  S. Ashley,et al.  RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine , 2004, Oncogene.